Full-Time

Senior Director

Biostatistics

Spyre Therapeutics

Spyre Therapeutics

11-50 employees

Clinical-stage biotech antibodies for IBD

Compensation Overview

$275k - $290k/yr

+ Bonus + Equity Grants

Remote in USA

Remote

Category
Biology & Biotech (2)
,
Required Skills
SAS
R
SAP Products
biostatistics
Requirements
  • A PhD Degree in Biostatistics, Statistics, or a related field with at least 10-12 years of experience in biostatistics within the pharmaceutical, biotech, or CRO industry.
  • Experience with regulatory submissions and interactions with regulatory agencies.
  • Proficiency in statistical software (e.g., SAS, R) and data management systems.
  • Experience with CDISC standards including Study Data Tabulation Model, Analysis Data Model, and Clinical Data Acquisition Standards Harmonization (CDASH).
  • Successful track record of working independently in a matrixed organization and providing solutions to emerging problems.
  • Excellent communication and interpersonal skills, along with organizational skills.
  • Ability to work collaboratively in a multidisciplinary team environment.
Responsibilities
  • Lead the biometrics team including statistician, data manager, and statistical programmer at a program level.
  • Provide statistical input to strategic planning, study design, protocol development, sample size calculation, case report form design, results interpretation, clinical study report, and address questions from regulatory agencies.
  • Promote research of advanced and innovative statistical methods to increase probability of success of clinical studies.
  • Author and develop statistical analysis plans (SAPs), and work with extended team or vendor in developing specification for derived variables, templates of statistical tables, figures, and listings.
  • Provide guidance to study team on all aspects of statistical activities; collaborate closely with data manager to ensure high-quality data.
  • Participate in cross-functional study-related activities; work collaboratively with Clinical Development, Clinical Operations, Clinical Data Managers, Pharmacovigilance and Epidemiology, Regulatory, Project Management, Translational Medicine, and other staff and vendors to meet project deliverables and timelines.
  • CRO / Vendor Oversight: Establish procedures through regular interaction, setting expectations on deliverables and timelines; ensure deliverables are accurate and delivered according to timelines.
  • Global Health Authority Interaction: Contribute to documents submitted to Health Authorities globally by providing input for the interaction or by writing the interaction document; may participate in meetings or teleconferences with Health Authorities.
  • Coordinate with internal and external team members to prepare the statistical analyses for interim analyses, DSUR updates, periodic safety updates, and other ad hoc analyses.
  • Build and develop efficient biostatistical processes and standards.
  • Other duties as assigned.
Desired Qualifications
  • Working knowledge of Bayesian methodology and causal inference is preferred.
  • Experience in people management is preferred.

Spyre Therapeutics develops long-acting antibody therapies for inflammatory bowel disease, including anti-α4β7 and anti-TL1A programs for ulcerative colitis and Crohn’s disease. These antibodies target immune pathways to reduce gut inflammation, aiming for durable effects, easier dosing, and potential for combination therapies. The company shifted from engineered enzymes for rare metabolic diseases to immunology-focused biologics, deprioritizing pegzilarginase and maintaining it only as historical activity. Its goal is to discover, develop, and potentially commercialize durable antibodies that address large, underserved GI patient populations.

Company Size

11-50

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • $403M raised at $62/share in April 2026 extends cash runway through key readouts.
  • SPY002 SKYWAY RA topline data expected Q3 2026 after accelerated enrollment.
  • SPY002 and SPY003 SKYLINE data due mid-2026 and Q3 2026 validate combos.

What critics are saying

  • SPY002 fails SKYLINE mid-2026 readout, drops stock 50-70% versus Sanofi's sarilumab.
  • SPY003 underperforms Q3 2026 from immunogenicity, loses to AbbVie's Skyrizi.
  • $400M annual burn forces dilutive financing at $20-30/share by end-2027.

What makes Spyre Therapeutics unique

  • SPY001 achieves 40% clinical remission and 51% endoscopic improvement in SKYLINE Part A.
  • YTE-modified antibodies enable quarterly or biannual dosing unlike Entyvio's biweekly schedule.
  • SKYLINE platform tests monotherapies and combinations of α4β7, TL1A, IL-23 targets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Spyre Therapeutics who can refer or advise you

Benefits

Unlimited Paid Time Off

Remote Work Options

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Equity

Health Savings Account/Flexible Spending Account

Wellness Program

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Professional Development Budget

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

33%

1 year growth

372%

2 year growth

420%
Spyre Therapeutics
Apr 14th, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock | Mon, 04/13/2026 - 16:47

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory

Seeking Alpha
Apr 13th, 2026
Spyre Therapeutics launches $300M public stock offering

Spyre Therapeutics has launched a $300 million underwritten public offering of common stock. The company may grant underwriters the option to purchase an additional $45 million in shares within 30 days. All shares in the offering will be sold directly by the company.

Yahoo Finance
Apr 8th, 2026
Spyre CEO sells $740K in stock after 300% surge as key Q3 data nears

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock for approximately $740,000 on 1 April 2026, according to an SEC filing. The transaction, executed under a Rule 10b5-1 trading plan adopted in June, represented 2.33% of his direct holdings and follows a roughly 300% share price increase over the past year. The sale appears to be routine profit-taking rather than a change in outlook. Spyre recently accelerated a key clinical catalyst, with its SKYWAY rheumatoid arthritis sub-study now expected to deliver topline data in Q3 2026 after completing enrolment ahead of schedule. Additional readouts across psoriatic arthritis and axial spondyloarthritis remain on track for Q4. The biotechnology company, valued at $4 billion, develops monoclonal antibody therapeutics targeting inflammatory bowel disease.

Aeglea BioTherapeutics
Mar 27th, 2026
Aeglea BioTherapeutics Announces Pricing of Initial Public Offering

Apr. 7, 2016- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the pricing of its initial public offering of 5,000,000 shares

Yahoo Finance
Mar 22nd, 2026
Spyre Therapeutics trades at 5.8x price-to-book despite $126M loss and 47% gap to analyst target

Spyre Therapeutics has raised investor attention following a 127% one-year total return, despite a recent 2.5% one-day decline. The stock trades at $41.25, approximately 47% below the average analyst price target of $60.79. The company's price-to-book ratio of 5.8x sits well above the US biotechs industry average of 2.5x, though below a peer group average of 9.4x. This suggests the market is pricing in significant premium for its inflammatory bowel disease and rheumatic conditions pipeline. Spyre Therapeutics remains loss-making, reporting net losses of $126.5 million and generating less than $1 million in revenue. The elevated valuation relative to its balance sheet reflects investor expectations for future growth, though clinical programme outcomes remain uncertain.